ABPRO HOLDINGS INC C/WTS 12/11/2029 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.08

EPS: As of FY2025 Q1, the actual value is USD -0.08.

EBIT: As of FY2025 Q1, the actual value is USD -2.958 M.

The company did not generate revenue during the three months ended March 31, 2025 and 2024.

Net Income (Loss): The company reported a net loss of - $3,887 for the three months ended March 31, 2025, compared to a net income of $636 for the same period in 2024.
Research and Development Expenses: Decreased by $0.7 million for the three months ended March 31, 2025, primarily due to the decrease in personnel being on furlough since October 2024.
General and Administrative Expenses: Increased by $0.8 million for the three months ended March 31, 2025, primarily due to an increase in costs of operating as a public company.

Net Cash Used in Operating Activities: - $1,719 for the three months ended March 31, 2025, compared to - $2,848 for the same period in 2024.
Net Cash Provided by Financing Activities: $132 for the three months ended March 31, 2025, compared to $2,345 for the same period in 2024.

Weighted Average Shares Outstanding: Basic shares outstanding were 50,922,432 for the three months ended March 31, 2025, compared to 19,181,066 for the same period in 2024.

Core Business Focus: The company plans to initiate clinical trials for ABP-102 and ABP-201 in 2026, focusing on HER2+ solid tumors and wet age-related macular degeneration (Wet AMD).
Non-Core Business: The company intends to monitor the market value of its listed securities and may consider available options to regain compliance with Nasdaq listing requirements.
Priority: The company expects to incur operating losses in the foreseeable future and plans to continue fundraising and seek alternate revenues from collaboration and license agreements.

EPS: As of FY2025 Q1, the actual value is USD -0.08.

EBIT: As of FY2025 Q1, the actual value is USD -2.958 M.

The company did not generate revenue during the three months ended March 31, 2025 and 2024.

Net Income (Loss): The company reported a net loss of - $3,887 for the three months ended March 31, 2025, compared to a net income of $636 for the same period in 2024.
Research and Development Expenses: Decreased by $0.7 million for the three months ended March 31, 2025, primarily due to the decrease in personnel being on furlough since October 2024.
General and Administrative Expenses: Increased by $0.8 million for the three months ended March 31, 2025, primarily due to an increase in costs of operating as a public company.

Net Cash Used in Operating Activities: - $1,719 for the three months ended March 31, 2025, compared to - $2,848 for the same period in 2024.
Net Cash Provided by Financing Activities: $132 for the three months ended March 31, 2025, compared to $2,345 for the same period in 2024.

Weighted Average Shares Outstanding: Basic shares outstanding were 50,922,432 for the three months ended March 31, 2025, compared to 19,181,066 for the same period in 2024.

Core Business Focus: The company plans to initiate clinical trials for ABP-102 and ABP-201 in 2026, focusing on HER2+ solid tumors and wet age-related macular degeneration (Wet AMD).
Non-Core Business: The company intends to monitor the market value of its listed securities and may consider available options to regain compliance with Nasdaq listing requirements.
Priority: The company expects to incur operating losses in the foreseeable future and plans to continue fundraising and seek alternate revenues from collaboration and license agreements.